Treating intermittent allergic rhinitis: A prospective, randomized, placebo and antihistamine-controlled study of Butterbur extract Ze 339

Phytotherapy Research

Volumn 19, Issue 6, 2005, Pages 530-537

  Schapowal, Andreas ^a  

^a Allergy Clinic   (Switzerland)

Author keywords

Butterbur extract Ze 339; Fexofenadine; Intermittent allergic rhinitis; Randomized prospective placebo controlled study

Indexed keywords

FEXOFENADINE; HERBACEOUS AGENT; PETASITES HYBRIDUS EXTRACT; PLACEBO; UNCLASSIFIED DRUG; ZE 339;

ADULT; AGED; ARTICLE; BUTTERBUR; CLINICAL FEATURE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAY FEVER; HEADACHE; HERB; HUMAN; JOB PERFORMANCE; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHT; PAIN; PHOTOSENSITIVITY DISORDER; PRACTICE GUIDELINE; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH PAIN; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LIVER; MALE; MIDDLE AGED; PETASITES; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

PETASITES;

EID: 25144490795     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1705     Document Type: Article

References (30)

1. Anon. 2005. Pharmavista Database of Swiss Products. www.pharmavista.ch (accessed 01.02.05)
2. Austen KF. 1981. Diseases of immediate type hypersensitivity. In Harrison's Principles of Internal Medicine, 9th edn. McGraw-Hill: Kogakusha, Tokyo.
3. Berman BA. 1988. Allergic rhinitis: mechanisms and management. J Allergy Clin Immunol 81: 980-984.
4. Bickel D, Roder T, Bestmann HJ, Brune K. 1994. Identification and characterization of inhibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med 60: 318-322.
5. Bousquet J, van Cauwenberge P, Khaltaev N. 2001. From allergic rhinitis and its impact on asthma (ARIA) in collaboration with the World Health Organization. J Allergy Clin Immunol 108(Suppl 5): S147-S334.
6. British National Formulary. 2002. Antihistamines, hyposensitisation, and allergic emergencies. In British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain.
7. Brune K, Bickel D, Peskar BA. 1993. Gastro-protective effects by extracts of Petasites hybridus: the role of inhibition of peptido-leukotriene synthesis. Planta Med 59: 494-496.
8. Di Lorenzo G, Pacor ML, Pellitteri ME et al. 2004. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34: 259-267.
9. EMEA. Herbal Medicines Products Working Party: Working Documents and Committee on Proprietary Medicinal Products Guidelines. European Medicines Evaluation Agency: www.emea.eu.int
10. FDA. Fexofenadine, Summary Basis for Approval. Studies PJPR009 and PJPR0010. www.fda.gov
11. Gray RD, Haggart K, Lee DK et al. 2004. Effects of butterbur treatment in intermittent allergic rhinitis: a placebo-controlled evaluation. Ann Allergy Asthma Immunol 93: 56-60.
12. Jackson CM, Lee DKC, Lipworth BJ. 2004. The effects of butterbur on the antihistamine and allergen cutaneous response. Asthma Immunol 92: 250-254.
13. Knapp HR. 1990. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 323: 1745-1748.
14. Lee DKC, Carstairs IJ, Haggart CM et al. 2003. Butterbur, a herbal remedy attenuates adenosine phosphate-induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy 33: 882-886.
15. Lee DK, Gray RD, Robb FM, Fujihara S, Lipworth BJ. 2004. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 34: 646-649.
16. Lee DKC, Haggart K, Robb FM et al. 2004. Butterbur, a herbal remedy, confers complementary anti-inflammatory activity is asthmatic patients receiving inhaled corticosteroids. Clin Exp Allergy 34: 110-114.
17. Meier B, Meier-Liebi M. 1994. Drug Monograph Petasites. In Hagers Handbuch der pharmazeutischen Praxis, 5th edn. Hänsel R, Keller K, Rimpler H, Schneider G (eds). Springer Verlag: Berlin.
18. Meltzer EO. 1997. The prevalence and medical and economic impact of allergic rhinitis in the United States. Allergy Clin Immunol 99: S805-S828.
19. Parikh A, Seadding GK. 1997. Seasonal allergic rhinitis. Br Med J 314: 1392-1395.
20. Schapowal A (on behalf of Petasites Study Group). 2002. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. Br Med J 324: 144-146.
21. Schapowal A (on behalf of Petasites Study Group). 2004. Butterbur Ze 339 for the treatment of intermittent allergic rhinitis: Dose-dependent efficacy in a prospective, double-blind, placebo-controlled study. Arch Otolaryngol Head Neck Surg 130: 1381-1386.
22. Schellenberg R. 2001. Treatment for the premenstrual syndrome with Agnus castus fruit extract: prospective, randomised, placebo controlled study. Br Med J 322: 134-137.
23. Spilker B, Schoenfelder J. 1991. Physician's global evaluation. In Data Collection Forms in Clinical Trials. Raven Press:.
24. Steiner R, Hauk A, Tratz W. 1998. Verfahren zur Herstellung von phytochemisch wirksamen Extrakten aus Pflanzenmaterial von Petasites hybridus. Intern. Patent application PTC/CH 98/00437 (12.10.98).
25. Thomet OAR, Wiesmann UN, Schapowal A, Bizer C, Simon HU. 2001. Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol 61: 1041-1047.
26. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance: Allergic Rhinitis: Clinical Development Programs for Drug Products (Protocol Issues and Elements; Data Analysis Issues). http://www.fda.gov/cder/ guidance/index.htm
27. Wheatley D. 1997. LI160, an extract of St John's wort versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 30 (Suppl): 77-80.
28. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. 2002. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 32: 1504-1509.
29. Woelk H. 2000. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 321: 536-539.
30. World Health Organization. 1996. Declaration of Helsinki on Human Rights of Subjects in Medical Research (as amended in Somerset West, Republic of South Africa, October 1996).